Ftse Mib
33.973,54
1,02%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.506,67
-0,77%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM) Notizie

Axsome Therapeutics Inc

AXSM
75,94
1,14 (1,52%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 00:03:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/5/202423:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202414:09IHMARKETNEWSIndex Futures Point to Strong Monday Opening, Building on..
06/5/202413:05EDGAR2Form 8-K - Current report
06/5/202413:00GLOBEAxsome Therapeutics Reports First Quarter 2024 Financial..
01/5/202413:00GLOBEAxsome Therapeutics Recognizes May as Mental Health..
15/4/202413:00GLOBEAxsome Therapeutics Highlights Innovative Neuroscience..
10/4/202413:00GLOBEAxsome Therapeutics to Report First Quarter 2024 Financial..
01/4/202413:00GLOBEAxsome Therapeutics Initiates ENGAGE Phase 3 Trial of..
25/3/202412:00GLOBEAxsome Therapeutics Announces Results of CRESCENDO..
25/3/202411:30GLOBEAxsome Therapeutics Announces AXS-12 Achieves Primary..
19/3/202412:00GLOBEAxsome Therapeutics Initiates PARADIGM Phase 3 Trial of..
05/3/202413:00GLOBEAxsome Therapeutics to Present at the Leerink Partners..
01/3/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202413:00GLOBEAxsome Therapeutics to Present at the TD Cowen 44th Annual..
23/2/202414:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202413:05EDGAR2Form 8-K - Current report
20/2/202413:00GLOBEAxsome Therapeutics Reports Fourth Quarter and Full Year..
20/2/202411:37IHMARKETNEWSMarket Cautiousness Ahead of Retail Giants’ Earnings; Oil..
14/2/202421:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202413:00GLOBEAxsome Therapeutics to Report Fourth Quarter and Full Year..
08/1/202413:10EDGAR2Form 8-K - Current report
04/1/202413:11EDGAR2Form 8-K - Current report
04/1/202413:00GLOBEAxsome Therapeutics Provides Preliminary Fourth Quarter and..
11/12/202313:00GLOBEAxsome Therapeutics Presents New Data and Post-Hoc Analyses..
07/12/202322:05EDGAR2Form 8-K - Current report
07/12/202313:00GLOBEAxsome Therapeutics Hosts Solriamfetol Virtual Investor..
22/11/202313:00GLOBEAxsome Therapeutics to Host Solriamfetol Virtual Investor..
21/11/202313:00GLOBEAxsome Therapeutics to Present at the Piper Sandler 35th..
06/11/202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202313:05EDGAR2Form 8-K - Current report
06/11/202313:00GLOBEAxsome Therapeutics Reports Third Quarter 2023 Financial..
06/11/202312:54IHMARKETNEWSMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla,..
02/11/202312:00GLOBEAxsome Therapeutics and the Global Alzheimer’s Disease..
31/10/202312:00GLOBEAxsome Therapeutics to Present at Upcoming Investor..
24/10/202313:00GLOBEAxsome Therapeutics Presents Results of the ACCORD trial of..
11/10/202323:03EDGAR2Form 8-K - Current report
11/10/202313:00GLOBEAxsome Therapeutics Appoints Dr. Sue Mahony to its Board of..
10/10/202313:00GLOBEAxsome Therapeutics to Report Third Quarter 2023 Financial..
02/10/202313:00GLOBEAxsome Therapeutics Joins the National Alliance on Mental..
21/9/202313:00GLOBEAxsome Therapeutics Joins the Global Narcolepsy Community in..
16/9/202300:32EDGAR2Form 144 - Report of proposed sale of securities
16/9/202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202313:03GLOBEAxsome Therapeutics Highlights Commitment to Innovating..
05/9/202313:00GLOBEAxsome Therapeutics to Present at Three Upcoming Investor..
15/8/202313:45EDGAR2Form 8-K - Current report
07/8/202323:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:02EDGAR2Form 8-K - Current report
07/8/202313:00GLOBEAxsome Therapeutics Reports Second Quarter 2023 Financial..
Apertura: 75,00 Min: 73,31 Max: 77,98
Chiusura: 74,80

La tua Cronologia

NASDAQ
AXSM
Axsome Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network